Ticker Details
CRISPR Therapeutics AG CRISPR Therapeutics AG is a gene editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics.
IPO Date:	October 19, 2016
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$5.55B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$1.78 | 3.07%
Avg Daily Range (30 D):	$1.59 | 2.91%
Avg Daily Range (90 D):	$1.56 | 2.95%

Institutional Daily Volume
Avg Daily Volume:	1.22M
Avg Daily Volume (30 D):	1.49M
Avg Daily Volume (90 D):	1.62M

Trade Size
Avg Trade Size (Sh.):	62
Avg Trade Size (Sh.) (30 D):	51
Avg Trade Size (Sh.) (90 D):	52

Institutional Trades
Total Institutional Trades:	6,697
Avg Institutional Trade:	$2.95M
Avg Institutional Trade (30 D):	$3.32M
Avg Institutional Trade (90 D):	$2.72M
Avg Institutional Trade Volume:	.05M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$5.78M
Avg Closing Trade (30 D):	$11.1M
Avg Closing Trade (90 D):	$9.42M
Avg Closing Volume:	92.85K

News

Jul 8, 2026 @ 2:22 PM Vertex’s Crinetics Deal Balances Growth wit... Source: Chris Markoch

Jul 6, 2026 @ 11:35 AM CRISPR Therapeutics vs. Viking Therapeutics: Which... Source: Erin Kennedy

Jul 3, 2026 @ 8:44 AM Gene Editing Therapeutics: Transforming Biopharmac... Source: Researchandmarkets.Com

Jul 3, 2026 @ 8:41 AM Global CRISPR-Based Drug Development Platforms Mar... Source: Researchandmarkets.Com

Jun 15, 2026 @ 8:10 PM Ocular Therapeutix vs. Prime Medicine: Which Healt... Source: Pamela Kock

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-6.2	$-1.28	$-1.35
Diluted EPS	$-6.2	$-1.28	$-1.35
Revenue	$4.1M	$1.46M	$.86M
Gross Profit
Net Income / Loss	$-568.53M	$-122.93M	$-130.61M
Operating Income / Loss	$-646.4M	$-130.25M	$-154.76M
Cost of Revenue
Net Cash Flow	$184.59M	$72.27M	$61.06M
PE Ratio